CLINICAL TRIALS PROFILE FOR LOPURIN

All Clinical Trials for LOPURIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03128879 ↗	Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Recruiting	AbbVie	Phase 2	2017-06-16	This phase II trial studies how well venetoclax and ibrutinib work in treating participants with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and ibrutinib may work better in treating participants with chronic lymphocytic leukemia/small lymphocytic lymphoma.
NCT03128879 ↗	Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 2	2017-06-16	This phase II trial studies how well venetoclax and ibrutinib work in treating participants with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and ibrutinib may work better in treating participants with chronic lymphocytic leukemia/small lymphocytic lymphoma.
NCT03128879 ↗	Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Recruiting	M.D. Anderson Cancer Center	Phase 2	2017-06-16	This phase II trial studies how well venetoclax and ibrutinib work in treating participants with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and ibrutinib may work better in treating participants with chronic lymphocytic leukemia/small lymphocytic lymphoma.
NCT01685411 ↗	Busulfan and Cyclophosphamide Followed By ALLO BMT	Terminated	Masonic Cancer Center, University of Minnesota	N/A	2013-01-01	This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.
NCT00899431 ↗	Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)	Terminated	Celgene Corporation	Phase 2	2009-05-06	The goal of this clinical research study is to learn if lenalidomide, when given with a stem cell transplant and chemotherapy (bendamustine, fludarabine, and rituximab), can help to control CLL. The safety of this treatment combination will also be studied.
NCT00899431 ↗	Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)	Terminated	M.D. Anderson Cancer Center	Phase 2	2009-05-06	The goal of this clinical research study is to learn if lenalidomide, when given with a stem cell transplant and chemotherapy (bendamustine, fludarabine, and rituximab), can help to control CLL. The safety of this treatment combination will also be studied.

Clinical Trial Conditions for LOPURIN

Condition Name

Condition Name for LOPURIN
Intervention	Trials
Chronic Lymphocytic Leukemia	2
Acute Lymphoblastic Leukemia	1
Acute Myeloid Leukemia	1
BTK Gene Mutation	1

Condition MeSH

Condition MeSH for LOPURIN
Intervention	Trials
Leukemia	3
Leukemia, Lymphoid	3
Leukemia, Lymphocytic, Chronic, B-Cell	2
Lymphoma	1

Clinical Trial Locations for LOPURIN

Trials by Country

+

−

Trials by Country for LOPURIN
Location	Trials
United States	3

Trials by US State

+

−

Trials by US State for LOPURIN
Location	Trials
Texas	2
Minnesota	1

Clinical Trial Progress for LOPURIN

Clinical Trial Phase

Clinical Trial Phase for LOPURIN
Clinical Trial Phase	Trials
Phase 2	2
N/A	1

Clinical Trial Status

Clinical Trial Status for LOPURIN
Clinical Trial Phase	Trials
Terminated	2
Recruiting	1

Clinical Trial Sponsors for LOPURIN

Sponsor Name

Sponsor Name for LOPURIN
Sponsor	Trials
M.D. Anderson Cancer Center	2
Celgene Corporation	1
Masonic Cancer Center, University of Minnesota	1

Sponsor Type

Sponsor Type for LOPURIN
Sponsor	Trials
Other	3
Industry	2
NIH	1

Clinical Trials, Market Analysis, and Projections for Lopurin (Allopurinol)

Introduction to Lopurin (Allopurinol)

Lopurin, commonly known by its generic name allopurinol, is a medication widely used to treat conditions such as gout, kidney stones, and high levels of uric acid in the body, particularly in patients undergoing cancer treatment. Here, we will delve into recent clinical trials, market analysis, and future projections for this drug.

Clinical Trials: Combination Therapy with Thiopurines

Recent clinical trials have explored the use of allopurinol in combination with thiopurines for the treatment of inflammatory bowel disease (IBD). The DECIDER study, a multicentre, randomised, placebo-controlled trial, aimed to evaluate the efficacy and safety of thiopurine-allopurinol combination therapy compared to standard thiopurine therapy in IBD patients[1][4].

Key Findings

• The trial, although terminated early due to slow recruitment, randomized 102 participants into two groups: 54 received thiopurine-allopurinol and 48 received thiopurine with a placebo.
• A higher proportion of patients in the thiopurine-allopurinol group achieved the primary outcome of symptomatic disease activity remission and reduced faecal calprotectin levels after 26 weeks.
• The combination therapy resulted in fewer adverse events and less frequent thiopurine dose adjustments.
• The study concluded that thiopurine-allopurinol therapy is safe, mitigates thiopurine adverse effects, and enhances tolerability without compromising efficacy.

Market Analysis for Allopurinol

Current Market Size and Growth

The global allopurinol market is anticipated to grow significantly over the forecast period of 2022-2029. According to Data Bridge Market Research, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 6% during this period[3].

Drivers of Growth

• Increasing Incidence of Gout and Kidney Stones: The rise in the incidence of gout and kidney stones globally is a major driver for the expansion of the allopurinol market.
• Geriatric Population and Healthcare Expenditure: The increasing geriatric population and rising healthcare expenditure are also contributing factors.
• Research and Development: Ongoing research and development activities and the emergence of new markets will provide beneficial opportunities for the allopurinol market.

Barriers to Growth

• High Cost and Side Effects: The high cost of the drug and associated side effects, such as loss of appetite, dizziness, and skin rash, are significant barriers to market growth.
• Lack of Awareness: Limited awareness about the benefits and proper use of allopurinol also hampers market expansion.

Market Projections for Allopurinol

Global Market Forecast

By 2029, the global allopurinol market is expected to show substantial growth driven by the factors mentioned above. Here are some key projections:

• Market Size: The market is projected to grow from its current size, with an estimated CAGR of 6% over the forecast period[3].
• End-Use Industries: The demand from various end-use industries, including hospitals, clinics, and pharmacies, will continue to drive market growth.
• Geographical Expansion: The market is expected to expand in regions with rising healthcare expenditure and increasing awareness about gout and kidney stone treatments.

Comparison with Other Therapeutic Markets

While allopurinol is primarily used for gout and kidney stones, its market dynamics can be compared to other therapeutic areas. For instance, the non-small cell lung cancer (NSCLC) market, which is driven by immunotherapies and targeted therapies, shows a different growth trajectory but highlights the importance of innovative treatments in driving market growth[2].

Key Takeaways

• Clinical Efficacy: Allopurinol, when combined with thiopurines, shows improved safety and efficacy in treating IBD patients.
• Market Growth: The global allopurinol market is expected to grow at a CAGR of 6% from 2022 to 2029.
• Drivers and Barriers: The market is driven by increasing incidence of gout and kidney stones, but is hindered by high costs and side effects.
• Future Prospects: Ongoing research and development, along with emerging new markets, will provide opportunities for market expansion.

FAQs

Q1: What is the primary use of Lopurin (allopurinol)?

Lopurin (allopurinol) is primarily used to treat conditions such as gout, kidney stones, and high levels of uric acid in the body.

Q2: What were the findings of the DECIDER study on thiopurine-allopurinol combination therapy?

The DECIDER study found that thiopurine-allopurinol combination therapy is safe, mitigates thiopurine adverse effects, and enhances tolerability without compromising efficacy in IBD patients.

Q3: What is the projected growth rate of the global allopurinol market?

The global allopurinol market is expected to grow at a CAGR of 6% from 2022 to 2029.

Q4: What are the major drivers of growth for the allopurinol market?

The major drivers include the increasing incidence of gout and kidney stones, rising geriatric population, and increasing healthcare expenditure.

Q5: What are the significant barriers to the growth of the allopurinol market?

The high cost of the drug and associated side effects, along with a lack of awareness, are significant barriers to market growth.

Sources

1. Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study) - PubMed.
2. NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025 - Drug Development.
3. Global Allopurinol Market - Industry Trends and Forecast to 2029 - Data Bridge Market Research.
4. Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study) - Wiley Online Library.